COPD - Nationale VersorgungsLeitlinien

119. Rasmussen JB,Glennow C. Reduction in days of illness after long-term treatment with N-
acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J
1988;1(4):351-5.
120. Parr GD,Huitson A. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest
1987;81(4):341-8.
121. Jackson IM, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic
bronchitis: a double-blind placebo controlled study. J Int Med Res 1984;12(3):198-206.
122. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation
rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
Eur J Respir Dis 1983;64(6):405-15.
123. Grassi C. Longterm oral acetylcysteine in chronic bronchitis. A double blind controlled study.
Multicenter Study Group. Eur J Respir Dis 1980;61 Suppl 111:93-108.
124. Meister R. Langzeittherapie mit Acetylcystein Retard-Tabletten bei Patienten mit chronischer
Bronchitis. Eine doppelblinde-placebokontrollierte Studie. Forum Prakt Allg Arzt 1986;25:198-205.
125. Poole PJ,Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease:
systematic review. BMJ 2001;322(7297):1271-4.
126. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in
chronic bronchitis: a quantitative systematic review. Eur Respir J 2000;16(2):253-62.
127. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in
chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled
clinical trials. Clin Ther 2000;22(2):209-21.
128. Olivieri D, Zavattini G, Tomasini G, Daniotti S, Bonsignore G, Ferrara G, Carnimeo N, Chianese R,
Catena E, Marcatili S. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term
multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind
study versus placebo. Respiration 1987;51 Suppl 1:42-51.
129. Decramer M, Rutten-van MM, Dekhuijzen PN, Troosters T, van HC, Pellegrino R, van Schayck CP,
Olivieri D, Del DM, De BW, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic
obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a
randomised placebo-controlled trial. Lancet 2005;365(9470):1552-60.
130. Kardos P, Cegla U, Gillissen A, Kirsten D, Mitfessel H, Morr H, Schultze-Werninghaus G, Sitter H,
Vogelmeier C, Voshaar T, Worth H, Eckardt V, Klimek L. Kurzfassung der Leitlinie der Deutschen
Gesellschaft fur Pneumologie zur Diagnostik und Therapie von Patienten mit akutem und
chronischem Husten. Med Klin (Munich) 2004;99(8):468-75.
131. Irwin RS, Boulet LP, Cloutier MM, Fuller R, Gold PM, Hoffstein V, Ing AJ, McCool FD, O'Byrne P,
Poe RH, Prakash UB, Pratter MR, Rubin BK. Managing cough as a defense mechanism and as a
symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998;114
Suppl 2 Managing:S133-81.
132. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating
agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary
disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute
Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997;156(6):1719-24.
133. Anthonisen NR. OM-8BV for COPD. Am J Respir Crit Care Med 1997;156(6):1713-4.
134. Winkelmann BR, Kullmer TH, Kneissl DG, Trenk D, Kronenberger H. Low-dose almitrine bismesylate
in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest
1994;105(5):1383-91.
© 2006
86